Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
11/2003
11/25/2003CA2117305C Substituted imidazole derivatives and their preparation and use
11/20/2003WO2003095678A1 Ldl receptor-related proteins 1 and 2 and treatment of bone or cartilage conditions
11/20/2003WO2003095667A2 Autoimmune conditions and nadph oxidase defects
11/20/2003WO2003095613A2 Nucleic acids, polypeptides, and methods for modulating apoptosis
11/20/2003WO2003095607A2 Role of p62 in aging-related disease
11/20/2003WO2003095498A1 Complex of organic medicines and beta-cyclodextrin derivatives and its preparing process
11/20/2003WO2003095452A1 Substituted pyrroline kinase inhibitors
11/20/2003WO2003095451A1 Carbamate-substituted pyrazolopyridines
11/20/2003WO2003095437A1 Aralkyl formyl-alkyl piperazine derivatives and their uses as cerebral nerve protective agent
11/20/2003WO2003095434A1 Benzoxazine derivatives as 5-ht6 modulators and uses thereof
11/20/2003WO2003095433A1 Hexahydro-pyridazine-3-carboxylic acid derivatives, pharmaceutical compositions containing same and preparation methods thereof
11/20/2003WO2003095432A1 Benzimidazole derivatives
11/20/2003WO2003095429A1 Active substances for the treatment, diagnosis and prophylaxis of diseases in which abnormal protein structures occur
11/20/2003WO2003095428A1 Dopamine receptor modulators as antipsychotic agents
11/20/2003WO2003095427A1 Spiro-ring compound
11/20/2003WO2003095420A1 Hydroxy tetrahydro-naphthalenylurea derivatives
11/20/2003WO2003094965A2 Modulation of neural stem cells with s1p or lpa receptor agonists
11/20/2003WO2003094955A1 Intracranial treatment of neuropsychiatric disorders by clostridial neurotoxins such as botulinum toxin
11/20/2003WO2003094946A1 Hepatoprotective activity of 2'-p-hydroxybenzoylmussaenosidic acid
11/20/2003WO2003094938A1 Method for reducing pain using oncolytic viruses
11/20/2003WO2003094934A1 Medicine for prevention of and treatment for amyloidosis
11/20/2003WO2003094932A1 Carbon monoxide as a biomarker and therapeutic agent
11/20/2003WO2003094914A1 Substantially pure solid form of the enol tautomer of 3-indolylpyruvic acid for use in the treatment of central nervous system disturbances
11/20/2003WO2003094903A1 A method of treatment
11/20/2003WO2003094896A1 A method to improve surface properties of pharmaceutical tablets
11/20/2003WO2003094861A2 Bis-benzimidazoles and related compounds as potassium channel modulators
11/20/2003WO2003094853A2 Compositions and methods for combating lower urinary tract dysfunctions with delta opioid receptor agonists
11/20/2003WO2003094842A2 Conjugates comprising central nervous system active drug
11/20/2003WO2003094831A2 Novel diazabicyclic biaryl derivatives
11/20/2003WO2003094830A2 Novel azacyclic ethynyl derivatives
11/20/2003WO2003087062A3 4-(heterocyclyl)-benzenesulfoximine compounds for the treatment of inflammation
11/20/2003WO2003070192A9 Compositions and methods for surrogate antibody modulation of an immune response and transport
11/20/2003WO2003065971A9 Non-myeloablative tolerogenic treatment with tyrphostins
11/20/2003WO2003055915A3 Human netrin receptor and uses thereof
11/20/2003WO2003054012A3 Leptin proteins
11/20/2003WO2003051276A3 Therapeutic heterocycles
11/20/2003WO2003050062A3 PRODUCTION OF CHIRALLY PURE α-AMINO ACIDS ADN N-SULFONYL α-AMINO ACIDS
11/20/2003WO2003049752A3 Gram positive bacteria preparations for the treatment of diseases comprising an immune dysregulation
11/20/2003WO2003042357A3 Enzymes
11/20/2003WO2003040183A3 Compounds for the diagnosis/prevention/treatment of alzheimer's disease
11/20/2003WO2003029210A3 Heteroaryl substituted tetrazole modulators of metabotropic glutamate receptor-5
11/20/2003WO2003027076A3 1h-imidazole derivatives having cb1 agonistic, cb1 partial agonistic or cb1- antagonistic activity
11/20/2003WO2003024357A3 Microfabricated nanopore device for sustained release of therapeutic agent
11/20/2003WO2003023018A3 A method for isolating, culturing and differentiating intestinal stem cells for therapeutic use
11/20/2003WO2003017946A3 Non-oxidatively metabolized compounds and compositions, synthetic pathways therefor, and uses thereof
11/20/2003WO2003016506A3 Secreted proteins
11/20/2003WO2003014079A8 Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments
11/20/2003WO2003012093A3 Regulator of calcineurin
11/20/2003WO2003008559A3 Novel analogs of choline for neuroprotection and cognitive enhancement in neurodegenerative disorders
11/20/2003WO2003006447A3 Interaction inhibitors of tcf-4 with beta-catenin
11/20/2003WO2003000864A3 Nucleic acid-associated proteins
11/20/2003WO2003000699A8 Substituted 1-oxa-2,8-diaza-spiro[4,5]dec-2-ene derivatives as medicaments for the treatment of pain
11/20/2003WO2003000021A3 Pancam nucleic acids and polypeptides
11/20/2003WO2002102315A3 QUINAZOLINE AND PYRIDO[2,3-d]PYRIMIDINE INHIBITORS OF PHOSPHODIESTERASE (PDE) 7
11/20/2003WO2002101045A3 Vanilloid receptor-related nucleic acids and polypeptides
11/20/2003WO2002095011A3 Inactivation of genes of the mep pathway
11/20/2003WO2002090530A3 Kinases and phosphatases
11/20/2003WO2002079249A3 New polynucleotides and polypeptides of the ifn$g(a)-21 gene
11/20/2003WO2002064734A3 Identification of target-specific folding sites in peptides and proteins
11/20/2003WO2002060462A8 Waay to obtain a extract with antidepressant and opioid antagonists properties and pharmaceutical products obtained from it
11/20/2003WO2002038744A3 Proteases
11/20/2003WO2002034915A3 Preferred segments of neural thread protein and methods of using the same
11/20/2003WO2002002506A8 Compounds to treat alzheimer's disease
11/20/2003WO2002002505A8 Compounds to treat alzheimer's disease
11/20/2003US20030216574 Pyrazine based inhibitors of glycogen synthase kinase 3
11/20/2003US20030216558 Novel compositions and methods for cancer
11/20/2003US20030216481 Cyclooxygenase inhibitors; osteoarthritis, rheumatoid arthritis, and other injuries that result from overuse
11/20/2003US20030216480 Reducing concentration chaperone protein; Alzheimer's disease; administering methoxychlor
11/20/2003US20030216475 Pharmaceutical composition
11/20/2003US20030216469 Cyclic amino acid derivatives useful as pharmaceutical agents
11/20/2003US20030216468 Thiol-based NAALADase inhibitors
11/20/2003US20030216461 Mixture of cyclooxygenase inhibitor, non-steroid antiinflammatory drug and acetaminophen; concurrent administering
11/20/2003US20030216458 Combination therapy for the treatment of migraine
11/20/2003US20030216456 Benzoxazole derivatives as novel melatonergic agents
11/20/2003US20030216454 Thiazolidine-4-one derivative, method for preparing the same, and pharmaceutical composition containing the same
11/20/2003US20030216446 Aryl ureas as kinase inhibitors
11/20/2003US20030216440 Process for preparing arylacetylaminothiazoles
11/20/2003US20030216430 3, 4-dihydroquinolin-2(1H)-one compounds as NR2B receptor antagonists
11/20/2003US20030216427 Amine derivatives for the treatment of apoptosis
11/20/2003US20030216424 Pyrroloquinoline quinone drugs for treatment of cardiac injury and methods of use thereof
11/20/2003US20030216419 Isomeric fused pyrrolocarbazoles and isoindolones
11/20/2003US20030216413 Catecholamine pharmaceutical compositions and methods
11/20/2003US20030216408 -4-substituted-N-(2-(4-(2,3-dihydro-benzo(1,4)dioxin-5-yl)-piperazin -1-yl)propy l)-N-pyridin-2-yl-benzamide or salt; useful as 5-HT1A receptor antagonists
11/20/2003US20030216404 Hydroxamic acid derivatives
11/20/2003US20030216401 Anti-obesity 1, 2, 3, 4, 10, 10a-hexahydropyrazino[1, 2-a] indoles
11/20/2003US20030216399 A dipeptide containing bi or tri-heterocylic ring with nitrogen atom which forms amide with carbonyl group of dipeptide chain; useful for treating osteoporosis, congestive heart failure and accelerates wound healing
11/20/2003US20030216395 Imidazo-triazine derivatives as ligands for GABA receptors
11/20/2003US20030216393 Administering to a patient in need an effective pain treating amount of a substituted 1-aminobutan-3-ol compound to treat migraines, hyperalgesia, inflammatory pain, and post-operative pain
11/20/2003US20030216387 Benzamide derivatives, particularly esterified cisapride derivatives
11/20/2003US20030216383 Compounds useful as reversible inhibitors of cysteine proteases
11/20/2003US20030216381 Can bind to Prostaglandin E2 receptors, especially, EP3 receptor and/or EP4 receptor and show antagonizing activity, and may be useful for prevention and/or treatment of disease, for example, pain, allergy, Alzheimer's disease, cancer
11/20/2003US20030216380 Novel gamma secretase inhibitors
11/20/2003US20030216379 Substituted fused pyrazolecarboxylic acid arylamides and related compounds
11/20/2003US20030216376 Crystalline forms of quetiapine hemifumarate
11/20/2003US20030216375 Sulfonamide substituted diphenyl thiourea compounds; use thereof in treating IL-8, GRO alpha, GRO beta, GRO gamma, NAP-2, and ENA-78 mediated diseases
11/20/2003US20030216368 Hormone replacement therapy
11/20/2003US20030216367 In perimenopausal, menopausal, and postmenopausal women through the sequential administration of combinations of conjugated estrogens and trimegestone
11/20/2003US20030216348 Aminosugar, glycosaminoglycan, and S-Adenosylmethionine composition for the treatment and repair of connective tissue
11/20/2003US20030216344 Antisense oligonucleotide against human acetylcholinesterase (AChE) and uses thereof
11/20/2003US20030216333 Antisense modulation of glycogen synthase kinase3 alpha expression
1 ... 1146 1147 1148 1149 1150 1151 1152 1153 1154 1155 1156 1157 1158 1159 1160 1161 1162 1163 1164 1165 1166 ... 1833